argenx SE
Company Profile
Business description
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Contact
Laarderhoogtweg 25
AmsterdamNH1101EB
NLDT: +31 107038441
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,639
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
stocks
The sectors set to soar on government spending
stocks
Chart of the Week: How private companies are reshaping public markets
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.70 | 45.20 | -0.50% |
| CAC 40 | 7,936.74 | 28.03 | -0.35% |
| DAX 40 | 23,526.32 | 207.70 | -0.88% |
| Dow JONES (US) | 46,712.43 | 199.87 | -0.43% |
| FTSE 100 | 9,658.15 | 77.63 | -0.80% |
| HKSE | 26,241.83 | 244.07 | -0.92% |
| NASDAQ | 22,708.21 | 345.79 | -1.50% |
| Nikkei 225 | 50,276.37 | 607.31 | -1.19% |
| NZX 50 Index | 13,599.21 | 22.40 | 0.16% |
| S&P 500 | 6,661.73 | 58.59 | -0.87% |
| S&P/ASX 200 | 8,769.70 | 40.80 | -0.46% |
| SSE Composite Index | 3,997.56 | 10.20 | -0.25% |